Ligand completes $739M acquisition of XOMA Royalty Corporation
AI Summary
Ligand Pharmaceuticals completed its acquisition of XOMA Royalty Corporation for $739 million, expanding its portfolio and market presence. This strategic deal underscores Ligand's growth strategy through significant corporate acquisitions.